The Journal of Arthroplasty, ABSTRACT| VOLUME 19, ISSUE 2, P258, FEBRUARY 01, 2004

Ximelagatran for prevention of venous thromboembolism in knee replacement

Charles W. Francis, MD Scott D. Berkowitz, MD Philip C. Comp, MD, PhD Anne W. Roth, MS Jennifer McElhattan, MS Clifford W. Colwell Jr, MD

Knee

In a prior study, ximelagatran, an oral direct thrombin inhibitor, dosed at 24 mg twice daily, showed similar efficacy to warfarin for prevention of venous thromboembolism following total knee replacement. The present study was conducted to determine if a higher dose of ximelagatran would be superior.

Link to article